Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12469273 | 0.98 | ABCG2 (0.42) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL3314700 | 0.78 | ITGB2 (0.52) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6416923 | 0.77 | NOTUM (0.50) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL5636846 | 0.75 | ITGB2 (0.48) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11437417 | 0.74 | ITGB2 (0.46) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL22317949 | 0.73 | ABCG2 (0.44) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL2491691 | 0.73 | ABCG2 (0.44) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL4308991 | 0.73 | ABCG2 (0.44) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL29450351 | 0.73 | ABCG2 (0.44) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 | |
| SCHEMBL3220813 | 0.73 | ABCG2 (0.44) | ABCG2ITGB2ICAM1ITGALSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
| EP-3980078-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD25 ANTIBODY DRUG CONJUGATE AND A FURTHER AGENT | ADC Therapeutics SA (CH) | 2022-04-13 | — | — | EP | disclosed |
| WO-2021249258-A1 | DEUTERATED PYRIDOPYRIMIDINONES AND THEIR USE AS HIGHLY SELECTIVE CYCLIN-DEPENDENT KINASE 2 INHIBITORS | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2021-12-16 | — | — | WO | disclosed |
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-2021000899-A1 | A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020249527-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD25 ANTIBODY DRUG CONJUGATE AND A FURTHER AGENT | ADC THERAPEUTICS SA (CH) | 2020-12-17 | — | — | WO | disclosed |
| EP-2768822-B1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARM SPA (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-9783512-B2 | Bicyclic methylene aziridines and reactions thereof | WISCONSIN ALUMI RESEARCH FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2016-03-17 | — | — | US | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
| CN-1610675-A | Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as CDC25 phosphatase inhibitors | SOD CONSEILS RECH APPLIC (FR) | 2005-04-27 | — | — | CN | disclosed |
| WO-2005000843-A2 | BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| EP-1469864-A1 | COMPOUNDS USEFUL AS A-3 ADENOSINE RECEPTOR AGONISTS | MUSCAGEN LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| EP-1451175-A1 | THROMBIN INHIBITORS | University of Ljubljana (SI) | 2004-09-01 | — | — | EP | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| WO-2003061670-A1 | COMPOUNDS USEFUL AS A3 ADENOSINE RECEPTOR AGONISTS | MUSCAGEN LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003048155-A1 | THROMBIN INHIBITORS | UNIVERSITY OF LJUBLJANA (SI) | 2003-06-12 | — | — | WO | disclosed |
| CN-1390219-A | Pyrazolopyrimidines as therapeutic agents | ABBOTT AG (DE) | 2003-01-08 | — | — | CN | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | AAAS, CYCS, AOC2 | ABCG2 2474/4885ITGB2 2975/4885ICAM1 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.